Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast

Breast Cancer Research and Treatment

Volumn 140, Issue 2, 2013, Pages 263-272

  Van Brussel, Aram S A ^a,b   Adams, Arthur ^b   Vermeulen, Jeroen F ^b   Oliveira, Sabrina ^a,b   Van Der Wall, Elsken ^b   Mali, Willem P Th M ^b   Van Diest, Paul J ^b   Van Bergen En Henegouwen, Paul M P ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Carbonic anhydrase IX; DCIS; Hypoxia; Molecular imaging; Monoclonal antibody; Near infrared

Indexed keywords

CARBONATE DEHYDRATASE IX; DYE; IRDYE800CW; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; TUMOR ANTIGEN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG DISTRIBUTION; FEMALE; FLUORESCENCE IMAGING; FLUORESCENT ANTIBODY TECHNIQUE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPOXEMIA; IMAGING SYSTEM; IMMUNOFLUORESCENCE; IN VITRO STUDY; INTRADUCTAL CARCINOMA; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE NECROSIS; TUMOR XENOGRAFT; ANIMAL; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL HYPOXIA; DIAGNOSTIC USE; IMMUNOLOGY; PATHOLOGY; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARBONIC ANHYDRASES; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL HYPOXIA; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICE; MOLECULAR IMAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 84881481421     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2635-6     Document Type: Article

References (41)

1. Sakorafas GH, Farley DR, Peros G (2008) Recent advances and current controversies in the management of DCIS of the breast. Cancer Treat Rev 34(6):483-497. doi: 10.1016/j.ctrv.2008.03.001
2. Cutuli B, Lemanski C, Le Blanc-Onfroy M, de Lafontan B, Cohen-Solal-Le-Nir C, Fondrinier E, Mignotte H, Giard S, Charra-Brunaud C, Auvray H, Gonzague-Casabianca L, Quetin P, Fay R (2013) Local recurrence after ductal carcinoma in situ breast conserving treatment. Analysis of 195 cases. Cancer Radiother 17(3):196-201. doi: 10.1016/j.canrad.2013.01.011
3. Lee LA, Silverstein MJ, Chung CT, Macdonald H, Sanghavi P, Epstein M, Holmes DR, Silberman H, Ye W, Lagios MD (2006) Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in situ of the breast. Am J Surg 192(4):416-419. doi: 10.1016/j.amjsurg.2006.06.005
4. Shamliyan T, Wang SY, Virnig BA, Tuttle TM, Kane RL (2010) Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ. J Natl Cancer Inst Monogr 41:121-129. doi: 10.1093/jncimonographs/lgq034
5. Stillebroer AB, Zegers CM, Boerman OC, Oosterwijk E, Mulders PF, O'Donoghue JA, Visser EP, Oyen WJ (2012) Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging. J Nucl Med 53(1):82-89. doi: 10.2967/jnumed.111.094896
6. Vermeulen JF, van Brussel AS, Adams A, Mali WP, van der Wall E, van Diest PJ, Derksen PW (2013) Near-infrared fluorescence molecular imaging of ductal carcinoma in situ with CD44v6-specific antibodies in mice: a preclinical study. Mol Imaging Biol 15(3):290-298. doi: 10.1007/s11307-012-0605-8
7. Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB, Ntziachristos V, Hollema H, Herek JL, Schroder CP, Kosterink JG, Lub-de Hoog MN, de Vries EG (2011) Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med 52(11):1778-1785. doi: 10.2967/jnumed.111.092833
8. Day KE, Beck LN, Heath CH, Huang CC, Zinn KR, Rosenthal EL (2013) Identification of the optimal therapeutic antibody for fluorescent imaging of cutaneous squamous cell carcinoma. Cancer Biol Ther 14(3):271-277. doi: 10.4161/cbt.23300
9. Zhang Y, Hong H, Engle JW, Yang Y, Barnhart TE, Cai W (2012) Positron emission tomography and near-infrared fluorescence imaging of vascular endothelial growth factor with dual-labeled bevacizumab. Am J Nucl Med Mol Imaging 2(1):1-13
10. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E (2001) Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93(4):309-314
11. Greijer AE, de Jong MC, Scheffer GL, Shvarts A, van Diest PJ, van der Wall E (2005) Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells. Cell Oncol 27(1):43-49
12. Gort EH, Groot AJ, van der Wall E, van Diest PJ, Vooijs MA (2008) Hypoxic regulation of metastasis via hypoxia-inducible factors. Curr Mol Med 8(1):60-67
13. Seeber LM, Horree N, Vooijs MA, Heintz AP, van der Wall E, Verheijen RH, van Diest PJ (2011) The role of hypoxia inducible factor-1alpha in gynecological cancer. Crit Rev Oncol Hematol 78(3):173-184. doi: 10.1016/j.critrevonc.2010. 05.003
14. Jans J, van Dijk JH, van Schelven S, van der Groep P, Willems SH, Jonges TN, van Diest PJ, Bosch JL (2010) Expression and localization of hypoxia proteins in prostate cancer: prognostic implications after radical prostatectomy. Urology 75(4):786-792. doi: 10.1016/j.urology.2009.08.024
15. Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ, Hinrichs B, van Diest PJ (2012) Fibrotic focus and hypoxia in male breast cancer. Mod Pathol 25(10):1397-1404. doi: 10.1038/modpathol.2012.101
16. Wykoff CC, Beasley N, Watson PH, Campo L, Chia SK, English R, Pastorek J, Sly WS, Ratcliffe P, Harris AL (2001) Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol 158(3):1011-1019. doi: 10.1016/S0002-9440(10)64048-5
17. Li XF, O'Donoghue JA (2008) Hypoxia in microscopic tumors. Cancer Lett 264(2):172-180. doi: 10.1016/j.canlet.2008.02.037
18. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E (2003) Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97(6):1573-1581. doi: 10.1002/cncr.11246
19. Wang Z, Shi Q, Gu Y, Shen Y, Sun M, Deng M, Zhang H, Fang J, Zhang S, Xie F (2011) Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1alpha in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol Res Pract 207(8):505-513. doi: 10.1016/j.prp.2011.06.009
20. van der Groep P, van Diest PJ, Smolders YH, Ausems MG, van der Luijt RB, Menko FH, Bart J, de Vries EG, van der Wall E (2013) HIF-1alpha overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers. PLoS ONE 8(2):e56055. doi: 10.1371/journal.pone.0056055
21. Chen CL, Chu JS, Su WC, Huang SC, Lee WY (2010) Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX. Virchows Arch 457(1):53-61. doi: 10.1007/s00428-010-0938-0
22. De Simone G, Supuran CT (1804) Carbonic anhydrase IX: biochemical and crystallographic characterization of a novel antitumor target. Biochim Biophys Acta 2:404-409. doi: 10.1016/j.bbapap.2009.07.027
23. Ahlskog JK, Schliemann C, Marlind J, Qureshi U, Ammar A, Pedley RB, Neri D (2009) Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br J Cancer 101(4):645-657. doi: 10.1038/sj.bjc.6605200
24. Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM, Old LJ, Russo P (2007) Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 8(4):304-310. doi: 10.1016/S1470-2045(07)70044-X
25. Oliveira S, van Dongen GA, Stigter-van Walsum M, Roovers RC, Stam JC, Mali W, van Diest PJ, van Bergen en Henegouwen PM (2012) Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Mol Imaging 11(1):33-46
26. Marshall MV, Draney D, Sevick-Muraca EM, Olive DM (2010) Single-dose intravenous toxicity study of IRDye 800CW in Sprague-Dawley rats. Mol Imaging Biol 12(6):583-594. doi: 10.1007/s11307-010-0317-x
27. Siebels M, Rohrmann K, Oberneder R, Stahler M, Haseke N, Beck J, Hofmann R, Kindler M, Kloepfer P, Stief C (2011) A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 29(1):121-126. doi: 10.1007/s00345-010-0570-2
28. Schackmann RC, van Amersfoort M, Haarhuis JH, Vlug EJ, Halim VA, Roodhart JM, Vermaat JS, Voest EE, van der Groep P, van Diest PJ, Jonkers J, Derksen PW (2011) Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. J Clin Invest 121(8):3176-3188. doi: 10.1172/JCI41695
29. Behbod F, Kittrell FS, LaMarca H, Edwards D, Kerbawy S, Heestand JC, Young E, Mukhopadhyay P, Yeh HW, Allred DC, Hu M, Polyak K, Rosen JM, Medina D (2009) An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res 11(5):R66. doi: 10.1186/bcr2358
30. MacAusland SG, Hepel JT, Chong FK, Galper SL, Gass JS, Ruthazer R, Wazer DE (2007) An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ. Cancer 110(12):2648-2653. doi: 10.1002/cncr.23089
31. Eccles SA (2011) The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol 55(7-9):685-696. doi: 10.1387/ijdb.113396se
32. Leone F, Perissinotto E, Cavalloni G, Fonsato V, Bruno S, Surrenti N, Hong D, Capaldi A, Geuna M, Piacibello W, Aglietta M (2003) Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. J Leukoc Biol 74(4):593-601. doi: 10.1189/jlb.0203068
33. Varia MA, Calkins-Adams DP, Rinker LH, Kennedy AS, Novotny DB, Fowler WC Jr, Raleigh JA (1998) Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol 71(2):270-277. doi: 10.1006/gyno.1998.5163
34. Picchio M, Beck R, Haubner R, Seidl S, Machulla HJ, Johnson TD, Wester HJ, Reischl G, Schwaiger M, Piert M (2008) Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-Gluco-RGD autoradiography. J Nucl Med 49(4):597-605. doi: 10.2967/jnumed.107.046870
35. Dolbier WR Jr, Li AR, Koch CJ, Shiue CY, Kachur AV (2001) [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. Appl Radiat Isot 54(1):73-80
36. Okuda K, Okabe Y, Kadonosono T, Ueno T, Youssif BG, Kizaka-Kondoh S, Nagasawa H (2012) 2-Nitroimidazole-tricarbocyanine conjugate as a near-infrared fluorescent probe for in vivo imaging of tumor hypoxia. Bioconjug Chem 23(3):324-329. doi: 10.1021/bc2004704
37. Tafreshi NK, Bui MM, Bishop K, Lloyd MC, Enkemann SA, Lopez AS, Abrahams D, Carter BW, Vagner J, Grobmyer SR, Gillies RJ, Morse DL (2012) Noninvasive detection of breast cancer lymph node metastasis using carbonic anhydrases IX and XII targeted imaging probes. Clinical Cancer Res 18(1):207-219. doi: 10.1158/1078-0432.CCR-11-0238
38. Bao B, Groves K, Zhang J, Handy E, Kennedy P, Cuneo G, Supuran CT, Yared W, Rajopadhye M, Peterson JD (2012) In vivo imaging and quantification of carbonic anhydrase IX expression as an endogenous biomarker of tumor hypoxia. PLoS ONE 7(11):e50860. doi: 10.1371/journal.pone.0050860
39. Fillies T, Werkmeister R, van Diest PJ, Brandt B, Joos U, Buerger H (2005) HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 5:84. doi: 10.1186/1471-2407-5-84
40. Horree N, van Diest PJ, van der Groep P, Sie-Go DM, Heintz AP (2007) Hypoxia and angiogenesis in endometrioid endometrial carcinogenesis. Cell Oncol 29(3):219-227
41. Seeber LM, Horree N, van der Groep P, van der Wall E, Verheijen RH, van Diest PJ (2010) Necrosis related HIF-1alpha expression predicts prognosis in patients with endometrioid endometrial carcinoma. BMC Cancer 10:307. doi: 10.1186/1471-2407-10-307